Molgramostim
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Pulmonary Alveolar Proteinosis
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Trial Timeline
Oct 22, 2025 → Dec 1, 2027
NCT ID
NCT06431776About Molgramostim
Molgramostim is a phase 3 stage product being developed by Savara for Autoimmune Pulmonary Alveolar Proteinosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06431776. Target conditions include Autoimmune Pulmonary Alveolar Proteinosis.
What happened to similar drugs?
0 of 12 similar drugs in Autoimmune Pulmonary Alveolar Proteinosis were approved
Approved (0) Terminated (3) Active (9)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06431776 | Phase 3 | Recruiting |
| NCT03482752 | Phase 3 | Terminated |
Competing Products
20 competing products in Autoimmune Pulmonary Alveolar Proteinosis